IBDEI34X ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,50067,1,3,0)
 ;;=3^Psoriasis,Unspec
 ;;^UTILITY(U,$J,358.3,50067,1,4,0)
 ;;=4^L40.9
 ;;^UTILITY(U,$J,358.3,50067,2)
 ;;=^5009171
 ;;^UTILITY(U,$J,358.3,50068,0)
 ;;=L50.9^^193^2487^326
 ;;^UTILITY(U,$J,358.3,50068,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50068,1,3,0)
 ;;=3^Urticaria,Unspec
 ;;^UTILITY(U,$J,358.3,50068,1,4,0)
 ;;=4^L50.9
 ;;^UTILITY(U,$J,358.3,50068,2)
 ;;=^5009204
 ;;^UTILITY(U,$J,358.3,50069,0)
 ;;=L53.8^^193^2487^150
 ;;^UTILITY(U,$J,358.3,50069,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50069,1,3,0)
 ;;=3^Erythematous Conditions NEC
 ;;^UTILITY(U,$J,358.3,50069,1,4,0)
 ;;=4^L53.8
 ;;^UTILITY(U,$J,358.3,50069,2)
 ;;=^88044
 ;;^UTILITY(U,$J,358.3,50070,0)
 ;;=L53.9^^193^2487^149
 ;;^UTILITY(U,$J,358.3,50070,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50070,1,3,0)
 ;;=3^Erythematous Condition,Unspec
 ;;^UTILITY(U,$J,358.3,50070,1,4,0)
 ;;=4^L53.9
 ;;^UTILITY(U,$J,358.3,50070,2)
 ;;=^5009210
 ;;^UTILITY(U,$J,358.3,50071,0)
 ;;=L54.^^193^2487^148
 ;;^UTILITY(U,$J,358.3,50071,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50071,1,3,0)
 ;;=3^Erythema in Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,50071,1,4,0)
 ;;=4^L54.
 ;;^UTILITY(U,$J,358.3,50071,2)
 ;;=^5009211
 ;;^UTILITY(U,$J,358.3,50072,0)
 ;;=L56.0^^193^2487^142
 ;;^UTILITY(U,$J,358.3,50072,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50072,1,3,0)
 ;;=3^Drug Phototoxic Response
 ;;^UTILITY(U,$J,358.3,50072,1,4,0)
 ;;=4^L56.0
 ;;^UTILITY(U,$J,358.3,50072,2)
 ;;=^5009214
 ;;^UTILITY(U,$J,358.3,50073,0)
 ;;=L56.1^^193^2487^141
 ;;^UTILITY(U,$J,358.3,50073,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50073,1,3,0)
 ;;=3^Drug Photoallergic Response
 ;;^UTILITY(U,$J,358.3,50073,1,4,0)
 ;;=4^L56.1
 ;;^UTILITY(U,$J,358.3,50073,2)
 ;;=^5009215
 ;;^UTILITY(U,$J,358.3,50074,0)
 ;;=L56.2^^193^2487^274
 ;;^UTILITY(U,$J,358.3,50074,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50074,1,3,0)
 ;;=3^Photocontact Dermatitis
 ;;^UTILITY(U,$J,358.3,50074,1,4,0)
 ;;=4^L56.2
 ;;^UTILITY(U,$J,358.3,50074,2)
 ;;=^5009216
 ;;^UTILITY(U,$J,358.3,50075,0)
 ;;=L56.3^^193^2487^308
 ;;^UTILITY(U,$J,358.3,50075,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50075,1,3,0)
 ;;=3^Solar Urticaria
 ;;^UTILITY(U,$J,358.3,50075,1,4,0)
 ;;=4^L56.3
 ;;^UTILITY(U,$J,358.3,50075,2)
 ;;=^5009217
 ;;^UTILITY(U,$J,358.3,50076,0)
 ;;=L57.0^^193^2487^13
 ;;^UTILITY(U,$J,358.3,50076,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50076,1,3,0)
 ;;=3^Actinic Keratosis
 ;;^UTILITY(U,$J,358.3,50076,1,4,0)
 ;;=4^L57.0
 ;;^UTILITY(U,$J,358.3,50076,2)
 ;;=^66900
 ;;^UTILITY(U,$J,358.3,50077,0)
 ;;=L60.0^^193^2487^164
 ;;^UTILITY(U,$J,358.3,50077,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50077,1,3,0)
 ;;=3^Ingrowing Nail
 ;;^UTILITY(U,$J,358.3,50077,1,4,0)
 ;;=4^L60.0
 ;;^UTILITY(U,$J,358.3,50077,2)
 ;;=^5009234
 ;;^UTILITY(U,$J,358.3,50078,0)
 ;;=L60.1^^193^2487^272
 ;;^UTILITY(U,$J,358.3,50078,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50078,1,3,0)
 ;;=3^Onycholysis
 ;;^UTILITY(U,$J,358.3,50078,1,4,0)
 ;;=4^L60.1
 ;;^UTILITY(U,$J,358.3,50078,2)
 ;;=^186837
 ;;^UTILITY(U,$J,358.3,50079,0)
 ;;=L60.2^^193^2487^271
 ;;^UTILITY(U,$J,358.3,50079,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,50079,1,3,0)
 ;;=3^Onychogryphosis
 ;;^UTILITY(U,$J,358.3,50079,1,4,0)
 ;;=4^L60.2
 ;;^UTILITY(U,$J,358.3,50079,2)
 ;;=^5009235
 ;;^UTILITY(U,$J,358.3,50080,0)
 ;;=L60.3^^193^2487^176
